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ABSTRACT
Purpose: We compared the outcome of transureth ral resection of the prostate and high energy 
microwave therm otherapy in  patients with benign prostatic hyperplasia.
M aterials and Methods: Of 52 patients w ith symptomatic benign prostatic hyperplasia 21 
(mean age plus or m inus standard  deviation 69.6 ± 8.5 years) were treated with transu re th ra l 
resection of the  prostate  and 31 (mean age 69.3 ± 5.9 years) were treated with high energy 
microwave therm otherapy. P atien ts were assessed using the Madsen symptom score, m eas­
urem ents of voiding param eters, transrecta l ultrasound and cystometry, including pressure-flow 
analyses. Exam inations were repeated at fixed intervals for up to 12 months after treatm ent.
Results: After tran su re th ra l resection and thermotherapy there was significant improvement 
in  all clinical param eters. At 1 year of followup symptomatic improvement was 78% in  the 
tran su re th ra l resection group versus 68% in  the therm otherapy group, with improvements in 
free flow ra te  of 100 and 69%, respectively. Both groups had significant relief of bladder outlet 
symptoms. No serious complications occurred in either group, while 1 patient in each group 
required repeat treatm ent.
Conclusions: Satisfactory resu lts were obtained after both treatm ents, with improvements 
following high energy microwave therm otherapy being in the same range as those after tra n s­
u re th ra l resection of the prostate.
K ey Words: prostatic hypertrophy; hyperthermia, induced; microwaves
In recent years increasing attention has focused on when 
and how patients with lower urinary tract symptoms caused 
by benign prostatic hyperplasia (BPH) should be treated. The 
gold standard instrumental treatment for BPH is still trans­
urethral resection of the prostate. Questions about the indi­
cations, results and complications of transurethral resection 
have focused interest on minimally invasive (anesthesia-free) 
treatment modalities that have become avail able 8 1 of 
which is transurethral microwave thermo therapy.7
Thermotherapy was designed to apply microwave energy 
deep within the lateral prostatic lobes while simultaneously 
cooling the urethral mucosa.9 Many thermo therapy devices 
have been developed for treatment of BPH.10"14 Most expe­
rience is available with the Prostatron* device, which has 
been used with 3 software programs having different fea­
tures.15-17 Version 2.0 is the most widely used software, and 
the results achieved for symptomatic improvement and 
changes in urinary performance were encouraging. The mean 
Madsen symptom score decreased from 13 before treatment 
to approximately 4 after treatment, while mean maximum 
flow improvement ranged from 2 to 3 ml. per second. Since 
clinical outcome could possibly be enhanced with higher in- 
traprost itic temperatures, resulting in thermal ablation and, 
thus, ca /ity formation, modifications to the operating soft­
ware have been made. Early reports on this high energy 
software version (Prostasoft 2.5) show a good subjective re­
sponse and excellent improvement in the objective parame­
ters.17«18
When evaluating a new technology for the treatment of
BPH, however, the results should be compared to those ob­
tained using a generally accepted method. We report on the 
1-year followup of a prospective randomized study comparing 
high energy microwave thermotherapy and transurethral 
resection of the prostate in patients with voiding complaints 
due to BPH.
Accepted for publication January 24, 1997.
* Technomed Medical Systems, Lyon, France.
PATIENTS AND METHODS
Between January 1994 and August 1995, 52 men 54 to 89 
years old (average age 69) with BPH were randomized 
(thermotherapy-to-transurethral resection ratio 3:2) into the 
trial. All patients provided written informed consent before 
participation after verbal explanation and reading an explan­
atory leaflet. The criteria for entry into the study were men 
45 years old or older who were candidates for transurethral 
resection with a clinically unequivocal benign prostate, total 
prostatic length 25 to 50 mm., prostate volume 30 to 100 
cm.3, symptoms of bladder outlet obstruction for longer than
3 months, Madsen symptom score 8 or greater, peak flow rate 
15 ml. per second, minimum voided volume 100 ml., post-void 
residual 350 ml. or less, and patient willingness and ability to 
comply with the study followup schedule and requirements. 
Patients with neurogenic disorders that may affect bladder 
function, prostatic carcinoma, prior surgery of the prostate, 
microwave possible sensitive implants (pacemaker or hip 
prosthesis), diabetic neuropathy, urinary retention requiring 
an indwelling catheter, renal impairment or an obstructed 
bladder neck due to an enlarged median lobe of the prostate, 
or those who were on medication prescribed for treatment of 
the prostate or bladder were excluded from the study.
Assessment and followup studies consisted of general his-
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Table 1. Baseline parameters and followup at 3, 6 a?id 12 months
Transurethral Transurethral
Resection of Microwave
Prostate Thermotherapy
Mean baseline parameters ± SD:
Age (yrs.) 69.6 ± 8.5 69.3 ± 5.9
Prostate vol. (cm.a) 45 ± 15 43 ± 12
Madsen symptom score 13.8 ± 4,2 13.3 ± 4.2
I-PSS 16.7 ± 5.6 18.3 ± 6.3
Max. flow rate (ml./sec.) 9.3 ± 3.4 10.0 ± 6.1
Compliance (ml.) 178.0 ± 84.1 193.5 ± 85.7
Residual urine (ml.) 91 ± 105 58 ± 78
No. pts. at followup (%):
Baseline 21 31
3 Mos. 21 31
6 Mos. 20 (1 lost to 27 (1 transure
followup)
12 Moa. 18 (1 bladder 
neck incision* 
1 Biicker op­
eration)
thral resection, 
1 died, 2 re­
fused therapy) 
26 (1 refused 
therapy)
tory (including the Madsen symptom score), physical exami­
nation with digital rectal examination, complete blood count, 
blood urea and creatinine measurements, and urine micros­
copy and culture. Urine cytology and prostate specific anti­
gen levels were always measured using the Hybritech* assay 
to exclude coexisting malignancy. Prostate configuration was 
assessed by transrectal ultrasound, with volume calculated 
using the ellipsoid formula with a 7.5 MHz. transrectal 
probe. If an abnormality was noted on digital rectal exami­
nation, prostate specific antigen or transrectal ultrasound 
ultrasound guided prostate biopsies were performed. Ure- 
throcystoscopy was done to judge the patency of the (prostat­
ic) urethra for strictures or an isolated obstructing prostatic 
middle lobe and to exclude intravesical pathological condi­
tions. Followup visits were scheduled at 1, 3, 6 and 12 
months after treatment, Urodynamic investigation with 
pressure-flow study analysis was performed at baseline and 
26 weeks after treatment. Ultrasound of the prostate was 
repeated at 12 and 52 weeks.
The flow rates were recorded using a Dantec Urodyn 1000 
flowmetert and the figures were corrected for artifacts by 
measuring the peak flow sustained for 2 seconds. Any re­
corded flow of greater than 15 ml. per second excluded the 
patient from the study. Eesidual urine was measured by 
suprapubic ultrasound using a 3.5 MHz. abdominal probe. To 
quantify the grade of bladder outlet obstruction, urodynamic 
investigation with pressure-flow analysis was performed. In­
travesical and rectal pressures were recorded using 8F cath­
eters mounted with micro tip sensors and detrusor pressure 
was calculated as the difference between both meas­
urements. The digitally stored pressure and flow data were 
analyzed by a program developed at our department. The 
parameters derived from the pressure-flow analysis were 
detrusor pressure at maximum flow, maximum flow rate, 
and the linear passive urethral resistance relation (obstruc­
tion grading according to the Schäfer nomogram). A patient 
is considered to have urodynamic obstruction when detrusor 
pressure at maximum flow falls into the obstructed area of 
the Abrams-Griffiths nomogram19 or when the linear passive 
urethral resistance relation is 3 or more.
All thermotherapy treatments were performed on an out­
patient basis using the Prostatron device and software ver­
sion 2.5. The method of therapy has been described previ­
ously. Treatment duration was 60 minutes with increasing 
thermal dose up to 70 watts. To prevent thermal damage to 
urethral mucosa and the rectal wall, urethrally and rectally
:|: Hybritech, Inc., San Diego, California.
t  Dantec, Skovlunde, Denmark.
positioned thermal sensors provide continuous feedback sig­
nals about the temperature achieved. When the maximum 
allowed temperature is detected by 1 of these thermal sen­
sors the program automatically interrupts the treatment un­
til the temperature decreases to a preset level. Before treat­
ment a 100 mg. diclofenac suppository was administered and
2 mg, midazolam were injected intramuscularly. During 
treatment no additional anesthesia was given but, if neces­
sary, intravenous sedation was administered when patients 
experienced major discomfort, which was mostly expressed 
as an intense urge to void that sometimes was combined with 
an urge to defecate. Since initial experience showed urinary 
retention in nearly all patients, they were given a urethral 
catheter with a leg bag immediately after treatment.
Transurethral resection of the prostate was performed by 2 
experienced urologists with use of spinal anesthesia. The sur­
gical capsule was reached circumferentially from the bladder 
neck to the verumontanum using 24 Ch. resectoscopes. The 
specimen weight, operative time, and preoperative and post­
operative complications were recorded. Statistical analysis 
was done with Wilcoxon’s test for paired samples and the 
Mann-Whitney 2-sample U test for independent samples 
(nonparametric).
RESULTS
The entry data for both groups are shown in table 1. No 
statistically significant difference was found between the 
pretreatment measures and scores of the 2 groups. At base­
line 52 patients entered the study, of whom 31 underwent 
thermotherapy and 21 underwent transurethral resection of 
the prostate. At 1 year of followup 44 patients were available 
for analysis. Mean operative time was 51 minutes (range 35 
to 70) with a mean resected weight of 32 gm, (range 8 to 100). 
Followup also is shown in table 1. At 6 months in the ther­
motherapy group treatment failed in 1 patient who under­
went transurethral resection of the prostate, 1 died of a 
nontreatment related cause, 1 was lost to followup and 2 
refused further followup visits (1 of them had a good symp­
tomatic as well as a good objective response, while 1 experi­
enced even more complaints after treatment). At 12 months 
in this group 1 patient refused the last visit (also with a good 
subjective and objective response at 6 months). In the 
transurethral resection group at 12 months 1 patient under­
went bladder neck incision because of sclerosis and 1 un­
derwent cystectomy due to bladder cancer.
Both groups showed significant changes in symptom 
scores. At 12 months the mean Madsen symptom score im­
proved by 78% for the transurethral resection group and by 
68% for the thermotherapy group. Mean symptom scores 
improved from 13.3 ± 4.2 at baseline to 5.2 ± 4.1 at 3 
months, with stabilization occurring at 4.4 ± 4.4 at 6 months 
and 4.2 ± 4.6 at 1 year of followup for the thermotherapy 
group. Similar changes were noted for the transurethral re­
section group, with improvement from 13,8 ± 4.3 at baseline 
to 3.6 ± 3.2, 2.5 ± 2.3 and 2.8 ± 4.0 at 3, 6 and 12 months, 
respectively. Comparable changes were noted in the Interna­
tional Prostate Symptom Score (I-PSS). Also, mean maxi­
mum flow rate improved significantly from 10,0 ± 6.0 ml. per 
second at baseline to 15.1 ± 8.1 ml. per second at 3 months, 
and remained stable at 17.0 ± 7.0 and 16.9 ± 8.1 ml. per 
second at 6 months and 1 year, respectively, in the thermo- 
therapy group. For transurethral resection mean maximum 
flow rate improved from 9.3 ± 3.4 ml. per second at baseline 
to 19.1 ± 11.0, 14.7 ± 6.3 and 18,6 ml. per second at 3, 6 and 
12 months, respectively (fig. 1). Since it is easy for individual 
poor results to become lost in the mean data for the entire 
group, the 50% decrease in symptom scores and/or 50% in­
crease in maximum flow rates for both groups is presented in 
table 2. Morbidity is presented in table 3. All patients ac­
cepted and tolerated the thermo therapy well. For the ther-
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Fig. 1 . Outcome of subjective and objective parameters at baseline (bl) and followup (3, 6 and 12 months). A, Madsen symptom score, 
1-PSS. C, maximum flow rate (Qtnax). TUMT , transurethral microwave thermotherapy. TURP , transurethral resection of prostate.
me therapy group a prolonged need for catheterization was 
no ;ed compared to the transurethral resection group (mean 
12.7 versus 4.1 days, median 8 versus 4, respectively). In this 
group also a greater incidence of urinary tract infections was 
noted, frequently in combination with irritative voiding com­
plaints. The repeat treatment rate at 1 year of followup was 
within the same range in both groups.
When evaluating the changes in obstruction improvements 
were noted in each group (fig. 2). In the transurethral resec­
tion group the mean urethral resistance factor improved 
from 45.7 ± 16.5 to 21.1 ± 13.6 cm. water and the mean
T able  2, More than 50% improvement in Madsen symptom scores
and/or maximum flow rate at 52 weeks of followup
Improvement More 
Than 50%
No. Pts. (%)
Transurethral Transurethral 
Resection of Microwave 
Prostate Thermotherapy
Max. flow rate increase 10 (48) 10 (32)
Symptom score decrease 15 (71) 17(55)
Max. flow rate and 9(43) 7(23)
symptom score
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T a b le  3. Comparison o f groups at 1 year of followup
Transurethral
Microwave
Thermotherapy
Transurethral 
Resection of 
Prostate
Mean % improvement: 
Symptomatic 68 78
Uroflowmetry 69 100
Obstruction 43 46
Morbidity:
Days hospital admission 0 4.1 (4-5)
(range)
Days catheterization (range) 12.7(6-35) 4.1 (4-5)
No. urinary tract infections (%) 5 (16) 1 (4)
No, irritative voiding symp- 9 (29) 4 (19)
toms (%)
No. repeat treatment {%) 1 (3.2) 1 (4.7)
Hematuria requiring addi­ 0 3 (14, coagulation)
tional treatment (%)
No patient required blood transfusion.
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Pig. 2. Urodynamic change s^  in Abrams-Grifilths nomogram. A, 
after transurethral resection of prostate, B , after transurethral mi­
crowave thermotherapy. • ,  pretreatment value. A, posttreatment 
value. Pdet, detrusor pressure, Qmax, maximum flow, ml Is, ml. per 
second. cmH20 , cm. water.
linear passive urethral resistance relation improved from 
3.1 ± 1.4 to 1.1 ± 1.2. In the thermotherapy group the 
mean urethral resistance factor improved from 44.1 ±25.1 
to 25.1 ± 8.5 cm. water and the linear passive urethral
resistance relation improved from 3.3 ± 1.8 to 2.0 ± 0.9 
(table 4). According to the Abrams-Griffiths nomogram19 
76% of patients in the transurethral resection group and 
62% in the thermotherapy group were considered to have 
obstruction before treatm ent, while at 6 months 15 and 
40%, respectively, were still considered to have obstruc­
tion.
DISCUSSION
Thermotherapy has recently received Food and Drug Ad­
ministration approval and is appealing to many urologists 
primarily because of its ease of use, minimal morbidity and 
impressive safety profile compared to transurethral resection 
of the prostate. When using the lower energy protocol version 
software (Prostasoft 2.0) an overall significant symptomatic 
improvement has been reported in the majority of patients in 
conjunction with improvement in voiding parameters.20 
Since elevation of intraprostatic temperatures resulted in 
clinical improvement, version 2.0 was modified to provide 
more power leading to an increase in the energy delivered to 
the prostate. This new version of the operating software, 
Prostasoft 2.5, is currently under investigation. The early 
clinical results using this high energy thermotherapy are 
excellent and superior to those of earlier treatment proto- 
cols.18 In patients with larger prostates and moderate to 
severe bladder outlet obstruction the results seem even com­
parable to those of surgical therapy. However, to be able to 
challenge the predominant transurethral resection of the 
prostate as an appropriate surgical option for treatment of 
patients with BPH, thermo therapy should generally provide 
results comparable to those of transurethral resection. A 
comparison of the efficacy of high energy microwave thermo­
therapy to transurethral resection is possible only by per­
forming a randomized controlled trial. To our knowledge this 
is the first study conducted documenting the 1-year followup 
data of such a trial.
The level of improvement in the symptom scores was 
greater for the transurethral resection group than for the 
thermotherapy group. However, there appeared to be no sta­
tistically significant difference in symptomatic improvement 
between both groups. The objective improvement is ex­
pressed in uroflowmetry results, The absolute improvement 
is less for high energy microwave thermotherapy than for 
transurethral resection of the prostate but the difference 
between the improvements in maximum urinary flow for the 
2 treatment groups was not statistically significant (table 4). 
Although uroflowmetry results are associated with obstruc­
tive voiding, these parameters are not associated with the 
grade of obstruction and, therefore, they cannot be used to 
determine objectively whether outlet obstruction is re­
lieved.21 To quantify the grade of bladder outlet obstruction, 
urodynamic investigation with pressure-flow analysis is con­
sidered the gold standard.19 To judge the obstruction reliev­
ing capabilities of high energy microwave thermotherapy of 
the prostate urodynamic studies must be performed before 
and after treatment. A recent study indicated that high en­
ergy microwave thermotherapy is indeed capable of relieving
T ab le  4. Clinical and urodynamic results
Transurethral Resection of Prostate Transurethral Microwave Thermotherapy Surgery vs. 
Thermotherapy 
p ValueBefore 26 Wks. 52 Wks. p Value:!: Before 26 Wks, 52 Wks. p Value!i'
Max. flow rate (ml./sec.) 9.3 14.7 18.6 0.0024 10 17 16.9 0.0002 0,54561
Madsen symptom score 13.8 2,5 2.8 0.0003 13.3 4.4 4.2 0.0001 0,20101
Urethral resistance factor 45.7 21.1 0.003 44.1 25.1 0.02 0.01*
(cm. water)
Linear passive urethral 3.2 1.1 0.003 3,3 2 0.04 0,14f
resistance relation
:|: Significant according to Wilcoxon's rank test for paired samples and the Mann-Whitney U 2-sample test for independent samples, 
t  Not significant.
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bladder outlet obstruction.22 We found that in both groups 
there was a significant decrease in obstructive parameters 
(urethral resistance factor and linear passive urethral resis­
tance relation) but the decrease in the transurethral resec­
tion group was more pronounced. The difference between the 
decrease in obstructive parameters in both groups appeared
to be significant (taLle 4).
Despite many surgical and technical improvements, the 
rate of total morbidity related to transurethral resection of 
the prostate has remained unchanged during the years.23-25 
Therefore, a variety of alternative and minimally invasive 
treatment modalities are under investigation. The major 
complications, such as incontinence, transfusion and the 
transurethral resection syndrome, have not occurred dur­
ing transurethral microwave thermotherapy.26 The morbid­
ity of the microwave therapy following lower energy treat­
ment mainly consists of the need for catheterization in up to 
25% of patients during 1 week.lfi Following high energy mi­
crowave thermotherapy clinical outcome parameters have 
improved but also the morbidity caused by this treatment 
protocol is increased compared to lower energy protocols. The 
high energy treatment is well tolerated by the patients but 
oral pain medication must be administered before or during 
therapy in most cases.18 Moreover the need for transurethral 
catheterization after treatment increased as well as the in­
cidence of posttreatment irritative voiding complaints. In 
both groups the incidence of urinary tract infections was low 
and there was no need for transfusion while the repeat treat­
ment rate was within the same range. The main disadvan­
tage of transurethral resection of the prostate is the need for 
anesthesia and, consequently, hospitalization. Transurethral 
microwave thermotherapy can still be performed as an out­
patient procedure without general anesthesia.
Where should we position this high energy thermotherapy 
treatment? From the prospective randomized study of 
Dahlstrand et al comparing lower energy thermotherapy and 
transurethral resection of the prostate, we have learned that 
after both treatments there was improvement in all clinical 
parameters.27 The improvements in free flow rate and ob­
struction were more pronounced after transurethral resec­
tion. Serious complications occurred only in patients who 
underwent transurethral resection of the prostate. Moreover, 
the improvements with either treatment lasted for at least 5 
years in that study.28 We found similar symptomatic im­
provements in both groups, comparable to those noted by 
Dahlstrand and Pettersson.28 However, the improvement in 
uroflowmetry parameters is much more pronounced when 
using the high energy protocol and, in a subgroup of patients 
is in the same range as that after transurethral resection of 
the prostate. Furthermore, in contrast to lower energy pro­
tocols, bladder outlet obstruction is relieved in a considerable 
number of patients.22*29*30 We believe that the latter possibly 
reflects the durability of high energy microwave thermother­
apy. Although Dahlstrand et al stated that improvements 
following Prostasoft 2.0 treatment lasted for at least 5 
years,27 this could not be confirmed by others in large series 
of patients.31*32 Blute32 and de Wildt31 et al noted a repeat 
treatment rate approximating 50% at 3 to 4 years of followup. 
We strongly believe that high energy microwave thermother­
apy will aventually result in a more durable treatment in 
patients vith bladder outlet obstruction and a large prostate 
(more than 40 gm.). However, in patients with no or only 
minima: bladder outlet obstruction we recommend prefera­
bly the use of the lower energy software version. In these 
cases symptomatic improvement can be achieved with mini­
mal morbidity.
CONCLUSIONS
High energy thermotherapy is an operator independent 
treatment for BPH. Overall the objective and subjective im­
provement results are comparable to those of the gold stan­
dard transurethral resection of the prostate. However, the 
urodynamic results still show a significant difference in relief 
of obstruction after transurethral resection of the prostate 
and high energy thermotherapy, the clinical significance of 
which currently remains unknown. With acceptable low mor­
bidity high energy thermotherapy appears to be a safe and 
effective treatment with a low repeat treatment rate.
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EDITORIAL COMMENT
The authors describe a randomized study of 2 groups of patients 
with similar clinical parameters and bladder outlet obstruction sec­
ondary to BPH who underwent transurethral resection of the pros­
tate (21) or transurethral microwave thermotherapy (31) using a 
high energy protocol and who were followed for 1 year. They cleai'ly 
document the clinical results in each group and include pressure- 
flow studies to compare obstructive parameters before and after 
therapy. Statistically significant improvement in both groups in 
terms of subjective and objective parameters was obtained. However, 
the levels of improvement in symptom score, uroflowmetry and 
pressure-flow analysis were all more pronounced in the transure­
thral resection group, as adequately displayed in the data presented 
in table 4 and figure 1 . The authors contend that the results of their 
randomized trial with high energy thermotherapy suggest a more 
durable treatment than low energy (Prostasoft 2.0) therapy since the 
repeat treatment rate for this protocol is approximately 50% at 4 
years (reference 32 in article). The documentation of relief of bladder
outlet obstruction by pressure-flow analysis and the creation of a 
subvesical cavity in a subset of patients, which have not been noted 
with low energy protocols, are important observations.
The relief of obstruction appeared to be greater in the transure­
thral resection group with only 15% having obstruction according to 
the Abrams-Griffiths nomogram compared to 40% in the thermother­
apy group. An assessment of quality of life and sexual function after 
both treatments would have added to the study. An important con­
cern is the incidence of retrograde ejaculation, which was reported to 
be nil with thermotherapy versus greater than 50% with transure­
thral resection. Only longer followup will define the repeat treatment 
rate compared to transurethral resection and lower energy protocols. 
It is important to note that the morbidity of high en t^ y  microwave 
thermo therapy is greater than the low energy protocol with a greater 
need for procedural sedation and catheterization (mean 12.7 days). 
However, overall the therapy is well tolerated. In the last sentence 
the authors state that thermotherapy can be offered to patients with 
no or minimal bladder outlet obstruction. In what situation would 
the authors offer thermotherapy to a patient with no bladder outlet 
obstruction? High energy microwave thermo therapy is a treatment 
for men with lower urinary tract symptoms due to BPH.
Michael L. Blute
Department o f Urology 
Mayo Clinic 
Rochester, Minnesota
REPLY BY AUTHORS
The number of surgically treated patients with lower urinary tract 
symptoms has decreased significantly and alternative treatment 
options are numerous. Several interventional nonsurgical modalities 
have emerged during the last decade, and microwave technology is 
one of the most appealing options, applying thermal energy deep 
within the prostate adenoma. The advantages of these heat applica­
tors are 3-fold: 1 ) they are efficacious for patients with lower urinary 
tract symptoms due to BPH, 2) they have proved to be remarkably 
safe, demonstrating a significant decrease in short-term morbidity 
compared to transurethral resection of the prostate, and 3) they do 
not cause hemostasia problems, there is a lack of physiological stress 
and patients can be treated routinely on an outpatient basics,
In applying higher energy levels to prostatic tissue transurethral 
microwave thermotherapy of the prostate has evolved from a pure 
symptomatic treatment to a treatment with the capability of reliev­
ing obstruction. Although several phase II studies showed excellent 
results following high energy transurethral microwave thermother­
apy, the current study unequivocally positions this treatment option 
against transurethral resection. Indeed, the latter provides superior- 
objective and subjective results, although at the price of hospitaliza­
tion and need for anesthesia.
The advantage of microwave technology over surgery is embedded 
in its power to tailor treatment to individual need. In patients with 
lower urinary tract symptoms but no or only minimal bladder outlet 
obstruction the lower energy software version is recommended. 
Therapy results in significant symptomatic improvement, while only 
minimal gain in objective parameters is expected, since there is no 
obstruction that cannot be relieved. Because obstruction can be re­
lieved using the high energy version, this treatment is recommended 
for patients with moderate to severe bladder outlet obstruction 
caused by BHP. These patients have significant improvement in 
objective and subjective parameters. In patients treated with trans­
urethral resection this differentiation cannot be made, while mor­
bidity is at a different level. Moreover, transurethral microwave 
thermotherapy definitely outperforms transurethral resection in the 
preservation of sexual function, which is considered an important 
quality of life issue.
